PC
GCVRZ

PointState Capital’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

PointState Capital’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-7,305,164
Closed -$3.29M – 194
2017
Q1 		$3.29M Hold
7,305,164
– – 0.03% 119
2016
Q4 		$2.78M Buy
+7,305,164
New +$2.47M 0.04% 106

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return

PointState Capital's GCVRZ Position: Q2 2017 in Review

PointState Capital sold out of Sanofi Contingent Value Rights (GCVRZ) in Q2 2017, closing a stake of 7,305,164 shares — an estimated $3.29M sold.

PointState Capital first reported a position in GCVRZ in Q4 2016 and held it in 2 quarters. The position peaked at $3.29M in Q1 2017. 115 funds tracked by Wall St. Rank hold GCVRZ as of Q2 2017.

  • PointState Capital reported no remaining Sanofi Contingent Value Rights position as of Q2 2017 after selling out during the quarter.
  • PointState Capital sold 7,305,164 Sanofi Contingent Value Rights shares in Q2 2017, an estimated $3.29M.
  • PointState Capital first reported a position in Sanofi Contingent Value Rights in Q4 2016 and held it in 2 quarters.
  • PointState Capital's Sanofi Contingent Value Rights position peaked at $3.29M in Q1 2017.
  • 115 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q2 2017.

Based on PointState Capital's 13F filing for Q2 2017, filed 14 Aug 2017.